S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NYSE:ENZEnzo Biochem Stock Price, Forecast & News

$2.40
+0.02 (+0.84 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.33
Now: $2.40
$2.43
50-Day Range
$2.16
MA: $2.44
$3.02
52-Week Range
$1.56
Now: $2.40
$4.85
Volume360,281 shs
Average Volume929,665 shs
Market Capitalization$114.94 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing 'STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Read More
Enzo Biochem logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone212-583-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$81.17 million
Book Value$1.81 per share

Profitability

Net Income$2.49 million

Miscellaneous

Employees460
Market Cap$114.94 million
Next Earnings Date10/20/2020 (Estimated)
OptionableOptionable
$2.40
+0.02 (+0.84 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

How has Enzo Biochem's stock been impacted by COVID-19 (Coronavirus)?

Enzo Biochem's stock was trading at $2.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENZ stock has decreased by 16.1% and is now trading at $2.40.
View which stocks have been most impacted by Coronavirus
.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020.
View our earnings forecast for Enzo Biochem
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings data on Monday, June, 8th. The medical research company reported ($0.17) earnings per share for the quarter. The medical research company had revenue of $16.90 million for the quarter. Enzo Biochem had a negative net margin of 39.50% and a negative return on equity of 36.23%.
View Enzo Biochem's earnings history
.

Has Enzo Biochem been receiving favorable news coverage?

Media headlines about ENZ stock have been trending negative on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enzo Biochem earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Enzo Biochem
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,470,000 shares, an increase of 11.8% from the June 30th total of 2,210,000 shares. Based on an average daily volume of 1,140,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 5.6% of the company's shares are sold short.
View Enzo Biochem's Current Options Chain
.

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the following people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)
  • Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Evermore Global Advisors LLC (6.72%), Strs Ohio (0.44%), Corrado Advisors LLC (0.22%), Integrated Wealth Concepts LLC (0.05%) and UBS Group AG (0.03%). Company insiders that own Enzo Biochem stock include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani, Harbert Management Corp and Peter J Iv Clemens.
View institutional ownership trends for Enzo Biochem
.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Corrado Advisors LLC, and UBS Group AG.
View insider buying and selling activity for Enzo Biochem
.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, and Integrated Wealth Concepts LLC. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani, Harbert Management Corp, and Peter J Iv Clemens.
View insider buying and selling activity for Enzo Biochem
.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $2.40.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $114.94 million and generates $81.17 million in revenue each year. Enzo Biochem employs 460 workers across the globe.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is www.enzo.com.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.